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abirateroneprednisone (AbP) improve overall survival (OS) in patients with
mCRPC vs. mitoxantroneP (MP) or P alone, respectively. Examination of patient
and disease characteristics noted differences in the exposure to docetaxel and
discontinuation of docetaxel due to progressive disease. The current study: 1) con-
ducted systematic literature reviews of second-line treatment studies; 2) reviewed
NICE and IQWIG submissions; 3) reviewed the initial and updated OS data from the
TROPIC and COU-AA-301 studies; 4) interviewed clinical experts; and 5) performed
a meta-analysis of two first-line (1L) mCRPC studies to inform the ITC on the OS for
the two treatments and connect the network. Three comparisons were performed
using hazard ratios (HRs) for the MP vs. P: 1.0 (clinical expert opinion), 0.97 (1L
studies meta-analysis), and 0.90 (survival curve extraction). The Bucher ITC was
used with a HR (CbzP vs. AbP)1 favoring CbzP.RESULTS:Results based on updated
OS data were consistent across methodologies, with HR(OS, clinical)0.97 (95%CI:
0.78-1.21), HR(OS, meta-analysis)0.95 (95%CI: 0.69-1.30) and HR(OS, extrac-
tion)0.88 (95%CI: 0.63-1.21), but all HRs were not significantly different. This was
observed in the docetaxel-resistant subgroup as well; with HR(OS, clinical) 0.95
(95%CI: 0.70-1.28), HR(OS, meta-analysis) 0.92 (95%CI: 0.63-1.34) and HR(OS, ex-
traction)0.85 (95%CI: 0.59-1.24). These are different from the results presented in
the IQWIG submission assuming that MP has the same effect as P alone based on
initial OS data. CONCLUSIONS: Differences in results highlight the dependency of
ITCs on efficacy assumptions. Lack of equivalence in disease, comparators or pa-
tient characteristics contribute to uncertainty regarding conclusions, which fur-
ther emphasizes the fact that randomized prospective clinical trials are best suited
to fully evaluate the efficacy and safety of cancer treatments.
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OBJECTIVES: The Huntington Quality of Life Instrument (H-QoL-I) is the first self-
reported, disease-specific instrument developed to assess the health-related qual-
ity of life (HRQoL) of patients with Huntington’s disease (HD). It was originally
developed and validated for France and Italy, and later also validated for Germany,
Poland and the USA. This study aimed to validate the Spanish version of H-QoL-I
cross-culturally. METHODS: The original questionnaire included three subscales
assessing motor functioning, psychology and socializing (11 items). The instru-
ment was translated forwards and backwards by native speakers. A survey was
conducted with 59 patients. Face validity was tested through item completion and
overall understanding. Internal validity was tested, assessing internal consistency,
correlation matrix using item/dimension correlation and factorial structure. Exter-
nal validation was performed versus motor symptoms, behavioral symptoms, in-
dependence, and the EuroQoL 5D (EQ-5D). Differential item functioning (DIF) anal-
yses were performed versus data from the Italian and French versions, using
Zumbo criteria. RESULTS: Item response rates ranged from 87% to 97%. A floor
effect was found for three items. Results showed that the scale had a good reliabil-
ity (Cronbach’s alpha coefficients  0.75). Factor analyses demonstrated satisfac-
tory construct validity. Item internal consistency (IIC) and item discriminant valid-
ity criteria were met for most items (i.e. IIC was  0.40, and correlations between
items and their respective rest-scores in one dimension were all greater than cor-
relations with another dimension). The external validity was supported by corre-
lation of the different dimensions with the related clinical symptoms and related
generic QoL dimensions. The correlation between total H-QoL-I score and EQ-5D
index score was 0.78. No DIF was detected. CONCLUSIONS: These data support the
cross-cultural validity of the H-QoL-I to assess the health status of patients with HD
and integrate the patient perspective for Spain. A limitation of this study is the
small sample size.
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OBJECTIVES: To translate and examine the psychometric properties of the Malay-
sian version of the Osteoporosis Health Belief Scale (OHBS-M) among type 2 diabe-
tes patients (T2DM) and to determine the best cut-off value for OHBS-M with opti-
mum sensitivity and specificity. METHODS: A standard “forward–backward”
procedure was used to translate OHBS into Malay language. It was later validated
on a convenience sample of 250 T2DM outpatients between May and July 2011. The
psychometric assessment of this study was including validity (face validity, con-
tent validity ratio, and construct validity) and reliability (internal consistency and
test-retest). Sensitivity and specificity of OHBS-M were calculated using receiver
operating characteristic (ROC) curve analysis in comparison with the proxy gold
standard (quantitative ultrasound scan). RESULTS: The mean SD of OHBS-M
scores was 158.31 20.80. The Fleiss’ kappa, content validity ratio range and con-
tent validity index were 0.99, 0.75 to 1 and 0.886, respectively. Seven factors of the
OHBS-M were identified using exploratory factor analysis and were confirmed
through confirmatory factor analysis. Internal consistency and test–retest reliabil-
ity value were 0.89 and 0.61, respectively. The cut-off value of the OHBS-M was 169
with a sensitivity of 77.4% (95% CI 0.68- 0.84) and a specificity of 78.2% (95% CI 0.69-
0.85) to identify osteoporosis/osteopenia patients. The positive and negative pre-
dictive values were 78% (95% CI 0.68 - 0.85) and 77.6% (95% CI 0.68-0.84), respec-
tively. The area under the curve (AUC) for the OHBS-M was 0.877(95% CI 0.82-0.92).
According to QUS measurements, 20.4% were considered osteoporotic, while, 57.6
% osteopenic and 22 % normal. CONCLUSIONS: The findings of this study suggest
that the OHBS-M instrument is valid and reliable tool to be used in Malaysian
clinical setting.
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OBJECTIVES: Item response theory (IRT) modeling evaluated the metric underlying
generic physical function (PF) surveys including SF-36, PROMIS and new PF cate-
gorical rating items and tested whether scores could be estimated more efficiently
while maintaining forward-backward comparability. METHODS: Generalized Par-
tial Credit Model (GPCM) estimates of parameters for MOS SF-36 PF-10, PROMIS
6-item PF and new (easy-hard) PF categorical rating items and model fit were tested
in a probability sample representing the general US population (N 625). Analyses
included: (a) fit of GPCM for 35-item bank; (b) item utilization in computerized
adaptive tests (CAT), (c) % at ceiling and floor; (d) % for whom reliability  0.90
(reliable range); (e) equivalence of mean norm–based scores (mean50, SD10) for
all measures across mild, moderate and severe chronically-ill groups, and (f) valid-
ity in predicting physical and emotional health general summary measures at a
9-month follow-up. RESULTS: The GPCM fit the data and item parameter estimates
agreed very well with those previously reported for MOS and PROMIS PF items. In
tests of discriminant validity, group means differed substantially across severity
groups (RV 0.81 to 1.00) and score equivalence across methods within each group
was confirmed (all differences 1 point). RV’s for standardized PF scores estimated
from new E-H items were equivalent to PF-10 and PROMIS PF estimations. Predic-
tive validity was equivalent and substantial (across methods) for physical and
significant, but lower, for emotional outcomes at 9 months, as hypothesized. The
most efficient (reduced respondent burden, comparable or improved reliability and
validity) measure was a new 6-item PF using E-H items and an improved adaptive
survey logic. CONCLUSIONS: Findings support the standardization of the metric
underlying PF measures and extend choice of methods to include more efficient
categorical rating scales that maintain forward-backward score comparability. Im-
proved adaptive survey logic reduces respondent burden and increases the reliable
range for estimates of scores for familiar legacy measures. This approach warrants
application to other generic health domains and tests of translated items and
standardized parameters across countries and languages.
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OBJECTIVES: A utility value is a preference-based measure for a person’s health-
related quality of life at a given point in time. In clinical trials the standard is to
measure utilities based on e.g. EQ-5D or HUI-3. However, in rheumatoid arthritis
(RA) there has been a tradition of estimating utility values indirectly from HAQ-DI.
This study used data from a phase 2a trial in RA patients after treatment with
NNC0109-0012 to assess outcome differences applying various indirect mapping
algorithms. METHODS: At least five different indirect mapping algorithms (UV1-5)
that translates HAQ-DI to EQ-5D or HUI3 utility values have been published. These
were applied to a phase 2a, multicentre, randomised, double-blind, multiple-dose,
placebo-controlled, parallel group trial investigating the clinical efficacy of
NNC0109-0012 in RA patients with active disease (Results reported elsewhere).
Physical function was a secondary objective measured by the change in HAQ-DI
from baseline to week 12. The analysis was performed with an ANOVA with treat-
ment as fixed factor. The following five algorithms were used: UV1(EQ-5D)0.9567–
0.309*HAQ-DI, Min;Max(0.03;0.96); UV2(HUI3)0.76–0.28*HAQ-DI0.05*(if Fe-
male), Min;Max(-0.08;0.81); UV3(HUI3)0.76–0.28*HAQ-DI0.05*(if
Female)0.001*Age, Min;Max(-0.06;0.91); UV4(HUI3)0.74–0.17*HAQ-DI, Min;
Max(0.23;0.74); and UV5(HUI3)0.9527–0.2018*HAQ-DI, Min;Max(0.35;0.95).
RESULTS: After 12 weeks the mean utility improvement within the active-group
across algorithms was 0.11 (range: 0.08-0.14) and 0.03 (range: 0.02-0.05) in the pla-
cebo-group. When comparing utility improvements between active and placebo
group across algorithms the difference was most pronounced when using UV3 
0.10 (range: 0.06-0.10) taking HAQ-DI, sex and age into account. CONCLUSIONS:
Choice of mapping algorithm for conversion of HAQ-DI into utilities impacts the
outcome in term of utility improvements, although the differences are small. Fu-
ture clinical trials using direct assessment of utilities will substantiate the potential
benefits of NNC0109-0012 for patients suffering from RA. Direct elicitations can
also be used to shed additional light on the validity of available indirect mapping
algorithms.
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OBJECTIVES: To identify descriptors that patients who have different physical con-
ditions use to describe the quality and severity of their pain, and to examine com-
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